AstraZeneca collaborates with cancer research organisations to develop portfolio
This article was originally published in Scrip
Executive Summary
AstraZeneca has signed agreements with two research organisations, Cancer Research UK (CRUK) and the US-based Sarah Cannon Research Institute, that will allow the company to develop its experimental oncology products. Although the mechanisms of the interactions are different, both deals mean that AstraZeneca can advance its experimental compounds without drawing unnecessarily on its internal resources.